Deenan Pillay

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
    Susie Huntington
    Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
    BMC Infect Dis 14:127. 2014
  2. doi request reprint Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network
    Deenan Pillay
    Research Department of Infection, University College London, London, UK
    Antivir Ther 18:831-6. 2013
  3. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
  4. pmc Disease-associated XMRV sequences are consistent with laboratory contamination
    Stephane Hue
    MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, UK
    Retrovirology 7:111. 2010
  5. ncbi request reprint The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy
    Deenan Pillay
    Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
    AIDS 20:21-8. 2006
  6. ncbi request reprint Antiretroviral resistance in the developing world
    Deenan Pillay
    Department of Virology, University College London, London, UK
    J HIV Ther 12:95-6. 2007
  7. ncbi request reprint Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe
    Deenan Pillay
    Department of Virology, Windeyer Institute, Royal Free and University College Medical School, University College London, London, UK
    Antivir Ther 9:695-702. 2004
  8. ncbi request reprint Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
  9. ncbi request reprint Multidrug resistant HIV and rapid progression of disease reported from New York
    Deenan Pillay
    Centre for Virology, University College London, United Kingdom
    Euro Surveill 10:E050224.2. 2005
  10. ncbi request reprint The priorities for antiviral drug resistance surveillance and research
    Deenan Pillay
    Department of Infection, University College London, London W1T 4JF, UK
    J Antimicrob Chemother 60:i57-8. 2007

Collaborators

Detail Information

Publications119 found, 100 shown here

  1. pmc Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women
    Susie Huntington
    Centre for Paediatric Epidemiology and Biostatistics, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
    BMC Infect Dis 14:127. 2014
    ..Short-term zidovudine monotherapy (ZDVm) remains an option for some pregnant HIV-positive women not requiring treatment for their own health but may affect treatment responses once antiretroviral therapy (ART) is subsequently started...
  2. doi request reprint Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network
    Deenan Pillay
    Research Department of Infection, University College London, London, UK
    Antivir Ther 18:831-6. 2013
    ..Topics considered during the workshop included the implications of drug resistance for the selection of first-line regimens and sequencing of treatments, optimal surveillance strategies and prevention of mother-to-child transmission. ..
  3. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
    ..However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve...
  4. pmc Disease-associated XMRV sequences are consistent with laboratory contamination
    Stephane Hue
    MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, UK
    Retrovirology 7:111. 2010
    ..Controversy has arisen from the failure of some studies to detect XMRV in PC or CFS patients and from inconsistent detection of XMRV in healthy controls...
  5. ncbi request reprint The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy
    Deenan Pillay
    Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, UK
    AIDS 20:21-8. 2006
    ..Transmission of drug-resistant HIV-1 is well recognized. However, the impact of such transmission on natural history of infection remains unknown...
  6. ncbi request reprint Antiretroviral resistance in the developing world
    Deenan Pillay
    Department of Virology, University College London, London, UK
    J HIV Ther 12:95-6. 2007
  7. ncbi request reprint Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe
    Deenan Pillay
    Department of Virology, Windeyer Institute, Royal Free and University College Medical School, University College London, London, UK
    Antivir Ther 9:695-702. 2004
    ....
  8. ncbi request reprint Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom
    Deenan Pillay
    Centre for Virology, Royal Free and University College Medical School, University College, London, United Kingdom
    J Infect Dis 192:967-73. 2005
    ..Method 2 also nearly doubles estimates of numbers of individuals infected with multiclass drug-resistant virus. Our results identify an urgent need for new drugs within existing classes and new classes of antiretroviral therapy...
  9. ncbi request reprint Multidrug resistant HIV and rapid progression of disease reported from New York
    Deenan Pillay
    Centre for Virology, University College London, United Kingdom
    Euro Surveill 10:E050224.2. 2005
  10. ncbi request reprint The priorities for antiviral drug resistance surveillance and research
    Deenan Pillay
    Department of Infection, University College London, London W1T 4JF, UK
    J Antimicrob Chemother 60:i57-8. 2007
    ..g. combination therapies) to limit emergence of resistance, and a focus on prevention strategies to prevent transmission...
  11. doi request reprint The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns
    Alison J Marks
    Bradford University, UK
    J Theor Biol 262:1-13. 2010
    ..Stochastic models may therefore have an important role to play in interpreting differences in transmitted drug-resistance prevalence trends among epidemiological surveys...
  12. doi request reprint Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data
    Huw Price
    Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 15:203-11. 2010
    ..Here, we examined associations between the emergence of N348I and antiretroviral history in a large clinical database...
  13. doi request reprint Virological response to initial antiretroviral regimens containing abacavir or tenofovir
    Loveleen Bansi
    Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom
    J Infect Dis 200:710-4. 2009
    ..88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART...
  14. doi request reprint Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine
    Ravindra K Gupta
    Division of Infection and Immunity, University College London Medical School, London, United Kingdom
    Pediatr Infect Dis J 29:e57-62. 2010
    ..There are few medium-term virologic data in children from resource-limited settings taking adult fixed-dose-combination antiretroviral therapy (cART) without viral load monitoring...
  15. doi request reprint Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy
    Anna Maria Geretti
    Royal Free Hampstead NHS Trust, Department of Virology, University College London Medical School, Health Protection Agency, London, England
    Clin Infect Dis 48:1296-305. 2009
    ..Studies to date, however, have described treatment outcomes predominantly in persons with subtype B infection or compared subtype B with diverse non-B subtypes grouped together...
  16. doi request reprint Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    Loveleen K Bansi
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
    AIDS 22:349-56. 2008
    ..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression...
  17. pmc Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals
    Stephane Hue
    UCL MRC Centre for Medical Molecular Virology, University College London, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Virol 83:2645-54. 2009
    ..These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries...
  18. pmc Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care
    Susie E Huntington
    Medical Research Council MRC Centre of Epidemiology for Child Health, Institute of Child Health, University College London, London, UK
    AIDS 27:95-103. 2013
    ..To describe predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care...
  19. doi request reprint Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
    ..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors...
  20. ncbi request reprint Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors
    David Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:771-7. 2008
    ..These changes might be expected to affect the prevalence and patterns of protease resistance in the population of patients who experience treatment failure...
  21. doi request reprint Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
    Tristan J Barber
    Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
    J Antimicrob Chemother 67:995-1000. 2012
    ..Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs...
  22. ncbi request reprint Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 370:1923-8. 2007
    ..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure...
  23. pmc Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
    ..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...
  24. pmc Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays
    Ravindra K Gupta
    MRC Centre for Medical Molecular Virology, University College London, Windeyer Institute, London, UK
    AIDS 24:1651-5. 2010
    ..We wished to assess the contribution of full-length Gag to protease inhibitor susceptibility in viruses unexposed to protease inhibitors, in particular from the most common HIV-1 subtypes, namely subtype A and C...
  25. doi request reprint Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011
    ..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort...
  26. doi request reprint Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study
    Loveleen Bansi
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    J Acquir Immune Defic Syndr 52:391-6. 2009
    ..However, the definition of an ALT flare is arbitrary and the extent to which such increases represent normal fluctuations has not been explored...
  27. ncbi request reprint Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 13:675-85. 2008
    ..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine...
  28. doi request reprint Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010
    ..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
  29. doi request reprint Late diagnosis in the HAART era: proposed common definitions and associations with mortality
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    AIDS 24:723-7. 2010
    ....
  30. doi request reprint Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy
    Christos Mihailidis
    Chelsea and Westminster Hospital NHS Trust, London, UK
    AIDS 22:427-30. 2008
    ..Furthermore, the presence of V118I as the sole nucleoside reverse transcriptase inhibitor mutation should not be over-interpreted when deciding on therapeutic options...
  31. pmc CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK
    Mark Bower
    Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    Haematologica 94:875-80. 2009
    ..Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma...
  32. pmc Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study
    David I Dolling
    Medical Research Council Clinical Trials Unit, London, UK
    J Antimicrob Chemother 68:2339-43. 2013
    ..To determine protease mutations that develop at viral failure for protease inhibitor (PI)-naive patients on a regimen containing the PI atazanavir...
  33. pmc Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1
    Robert J Gifford
    Department of Infection, University College London, London, United Kingdom
    J Virol 81:13050-6. 2007
    ..The framework implemented here takes advantage of the vast amount of routinely generated HIV-1 sequence data and can provide epidemiological insights not readily obtainable through standard surveillance methods...
  34. doi request reprint The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  35. pmc Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study
    Huw Price
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS ONE 7:e49314. 2012
    ..This study aimed to determine the prevalence and incidence of HBV in the UK CHIC Study, a multicentre observational cohort...
  36. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  37. doi request reprint HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era
    Lucy Garvey
    Clinical Trials Centre, Winston Churchill Wing, St Mary s Hospital, London, W2 1NY, UK
    Eur J Neurol 18:527-34. 2011
    ..Data describing the incidence and survival of HIV-related central nervous system diseases (CNS-D) in recent years are sparse...
  38. doi request reprint Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)
    Charles F Gilks
    Imperial College, London, UK
    Antivir Ther 17:1363-73. 2012
    ..Boosted protease inhibitor (bPI) monotherapy (bPImono) potentially has substantial cost, safety and operational benefits. It has never been evaluated as second-line antiretroviral therapy (ART) in Africa...
  39. ncbi request reprint Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count
    Andrew N Phillips
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1717-21. 2007
    ..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART...
  40. ncbi request reprint Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity
    Robert Gifford
    Department of Infection, University College London, UK
    AIDS 20:1521-9. 2006
    ..However, it is not clear how reliable standard genotyping of these sequences is for describing HIV-1 genetic variation and for detecting novel genetic variants and epidemiological trends...
  41. pmc Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score
    Alessandro Cozzi-Lepri
    Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus, London, United Kingdom
    PLoS ONE 6:e25665. 2011
    ....
  42. ncbi request reprint Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
    Katherine J Lee
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 12:949-56. 2007
    ..To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS)...
  43. doi request reprint Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis
    Ravindra K Gupta
    UCL MRC Centre for Medical Molecular Virology, University College London Medical School, London, UK
    Lancet Infect Dis 9:409-17. 2009
    ..This Review highlights the need for cheap point-of-care viral-load tests to identify early viral failures and limit the emergence of resistance...
  44. doi request reprint Causes and consequences of incomplete HIV RNA suppression in clinical trials
    Anton Pozniak
    Chelsea and Westminster Hospital, London, United Kingdom
    HIV Clin Trials 10:289-98. 2009
    ..However, other methods may improve precision and increase statistical power...
  45. ncbi request reprint A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  46. ncbi request reprint Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters
    Krishnan Bhaskaran
    Medical Research Council Clinical Trials Unit, London, UK
    AIDS 18:1471-3. 2004
    ..The virological and host determinants of this possible phenomenon are worth further exploration...
  47. pmc Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
    Katherine A Sutherland
    University College London, London, United Kingdom
    PLoS ONE 10:e0137834. 2015
    ..We therefore characterized Gag-Protease phenotypic susceptibility in subtype A and D viruses circulating in East Africa following viral rebound on PIs...
  48. doi request reprint Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1
    Katherine A Sutherland
    Public Health England, London, UK
    J Gen Virol 95:190-200. 2014
    ..It also highlighted the importance of considering co-evolved Gag and protease when assessing PI susceptibility. ..
  49. pmc Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring
    Viktor von Wyl
    Research Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS ONE 7:e42834. 2012
    ..We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy...
  50. pmc Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
    Susie E Huntington
    Research Department of Infection and Population Health, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK
    BMC Med Res Methodol 12:110. 2012
    ..A methodology was developed to find and match records for women reported to both studies thereby obtaining clinical and treatment data on pregnant HIV-positive women not available from either dataset alone...
  51. doi request reprint The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK
    Katherine L Donegan
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 17:599-603. 2012
    ....
  52. pmc Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis
    Ravindra K Gupta
    Department of Infection, University College London, London, UK
    Lancet 380:1250-8. 2012
    ..We aimed to estimate changes in the prevalence of HIV-1 drug resistance in treatment-naive individuals with HIV since initiation of rollout in resource-limited settings...
  53. pmc The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains
    Jean L Mbisa
    Virus Reference Department, Microbiology Services, Colindale, Health Protection Agency, London, UK
    Retrovirology 8:31. 2011
    ..In this study we examined the genotypic, phenotypic and fitness correlates associated with the development of Q151M MDR in the absence of viral load monitoring...
  54. ncbi request reprint The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response
    Esteban Herrero-Martinez
    Department of Virology, Royal Free and University College Medical School, London, United Kingdom
    J Med Virol 72:187-93. 2004
    ..The relationship disappeared or was obscured after therapy (R = 0.24, P = 0.30 and R = 0.16, P = 0.50, respectively). Thus, we show that HAART affects the HCV specific humoral immune responses without affecting the HCV RNA level...
  55. doi request reprint Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions
    Alison E Brown
    Centre for Infections, Health Protection Agency, University College London, London, UK
    J Infect Dis 199:427-31. 2009
    ..Previous analyses may have incorrectly assigned transmission events to the acutely HIV infected when they were more likely to have occurred during chronic infection...
  56. doi request reprint Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials
    Ravindra Gupta
    Division of Infection and Immunity, University College London, London, United Kingdom
    Clin Infect Dis 47:712-22. 2008
    ..Resistance to antiretroviral combination therapy is associated with increased mortality. Understanding the relative risks of emerging resistance to first-line therapy is of importance for both resource-rich and resource-poor settings...
  57. ncbi request reprint Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
    ....
  58. pmc No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort
    Eleanor R Gray
    Department of Infection and Immunity, University College London, London, United Kingdom
    PLoS ONE 6:e18096. 2011
    ..It has also been suggested that the virus can be found circulating amongst the general population. The discovery has been controversial, with conflicting results from attempts to reproduce the original studies...
  59. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010
    ..To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK...
  60. pmc Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
    Anna Schultze
    Department of Infection and Population Health, University College London, London, UK
    J Int AIDS Soc 17:19737. 2014
    ..We sought to quantify the effect of resistance mutations on CD4 slopes in patients undergoing episodes of viral failure...
  61. pmc Persistence of HIV-1 transmitted drug resistance mutations
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 208:1459-63. 2013
    ..Our estimates are important for informing HIV transmission models. ..
  62. pmc Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups
    Stephane Hue
    Centre for Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, UK
    Proc Natl Acad Sci U S A 102:4425-9. 2005
    ..Our results provide insights into the complexity of HIV-1 epidemics that must be considered when developing HIV monitoring and prevention initiatives...
  63. ncbi request reprint Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients
    Caroline A Sabin
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 8:301-8. 2003
    ..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus...
  64. pmc Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration
    Ravindra K Gupta
    Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom
    Proc Natl Acad Sci U S A 106:20889-94. 2009
    ..Our observations emphasize the importance of tetherin in protecting mammals against viral infection and suggest that HIV-1 Vpu inhibitors may select active envelope mutants...
  65. pmc Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion
    Ravindra K Gupta
    Medical Research Council Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, London, United Kingdom
    PLoS Pathog 5:e1000443. 2009
    ..This work suggests that tetherin binding agents might protect it from viral encoded countermeasures and thus make powerful antivirals...
  66. pmc Hare TRIM5α restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes
    Adam J Fletcher
    MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, Windeyer Building, London, United Kingdom
    J Virol 84:12463-8. 2010
    ..We propose that, like primates, lagomorphs have been subject to selective pressure from TRIM5-sensitive viruses, possibly related to the endogenous lentivirus RELIK found in both rabbits and hares...
  67. ncbi request reprint UK HIV drug resistance database: background and recent outputs
    David Dunn
    MRC Clinical Trials Unit, London, UK
    J HIV Ther 12:97-8. 2007
  68. doi request reprint Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters
    L Waters
    Department of GU HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, UK
    HIV Med 12:289-98. 2011
    ..We investigated whether adverse responses to highly active antiretroviral therapy (HAART) associated with late HIV presentation are secondary to low CD4 cell count per se or other confounding factors...
  69. doi request reprint Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
    Andrew N Phillips
    HIV Epidemiology and Biostatistics Group, Department of Primary Care and Population Sciences, and Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, University College London, London, UK
    Lancet 371:1443-51. 2008
    ..Our aim was to study the potential consequences of such monitoring strategies, especially in terms of survival and resistance development...
  70. doi request reprint The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  71. pmc Phylodynamic and phylogeographic patterns of the HIV type 1 subtype F1 parenteral epidemic in Romania
    Jean L Mbisa
    Virus Reference Department, Microbiology Services, Health Protection Agency, London, United Kingdom
    AIDS Res Hum Retroviruses 28:1161-6. 2012
    ..Furthermore, phylogeographic analysis suggests that the root location of the parenteral epidemic was Bucharest...
  72. ncbi request reprint The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients
    Alan Winston
    Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS 16:2087-9. 2002
    ..Both genetic routes may compromise abacavir and tenofovir activity...
  73. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
    ..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK...
  74. pmc Management of paediatric HIV-1 resistance
    Ravindra K Gupta
    University College London, Windeyer Building, UK
    Curr Opin Infect Dis 22:256-63. 2009
    ..Similarly, well resourced settings face challenges regarding extensive resistance accumulated over the past decade or more, particularly resulting from suboptimal therapies...
  75. ncbi request reprint HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy
    Stephane Hue
    Division of Immunity and Infection, University of Birmingham and Regional Health Protection Agency, Birmingham Heartlands Hospital, London, UK
    AIDS 18:719-28. 2004
    ..We wished to assess the potential of using HIV-1 pol gene for the identification of transmissions events by phylogenetic means in the era of antiretroviral drug selective pressure...
  76. doi request reprint Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc
    Darius Armstrong-James
    Imperial College, St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    Antiviral Res 86:224-6. 2010
    ..Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection...
  77. doi request reprint Clinical epidemiology of HIV-associated end-stage renal failure in the UK
    Loveleen Bansi
    University College London Medical School, London, UK
    AIDS 23:2517-21. 2009
    ..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom...
  78. pmc HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination
    Stephane Hue
    Centre for Medical Molecular Virology, University College, London, United Kingdom
    AIDS Res Hum Retroviruses 28:220-4. 2012
    ..Overall, these data indicate that there have been multiple introductions of HIV-1 into this small rural town and surroundings with ongoing diversity being generated by recombination...
  79. doi request reprint The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy
    Ruth Bridget Ferns
    Division of Infection and Immunity, University College London, London, UK
    AIDS 23:2159-64. 2009
    ..To monitor HIV-1 integrase resistance mutations during raltegravir (RAL) therapy, including the impact of RAL interruption...
  80. ncbi request reprint Determinants of HIV drug resistance mutations in plasma virus after treatment interruption
    Daniella Chilton
    Mortimer Market Centre, Camden Primary Care Trust, London, UK
    AIDS 19:2174-5. 2005
    ..We conclude that resistance testing is of value up to 3 months after treatment interruption, and may convey some benefit up to 12 months...
  81. ncbi request reprint Transmission of HIV-1 drug resistance
    Julian W Tang
    Department of Virology, Windeyer Institute of Medical Sciences, Royal Free and University College Medical Schools, 46 Cleveland Street, London W1T 4JF, UK
    J Clin Virol 30:1-10. 2004
    ..This can lead to the transmission of drug-resistant strains of HIV to susceptible individuals. This can lead to suboptimal first-line therapy, if the resistance profile of the transmitted virus is unknown...
  82. ncbi request reprint The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis
    S Tariq Sadiq
    Camden and Islington Community NHS Trust and Department of Sexually Transmitted Diseaeases and Virology, Royal Free and University College Medical School, University College, London, UK
    AIDS 16:219-25. 2002
    ..High seminal plasma HIV-1 RNA loads (SVL) have been reported during gonococcal, non-gonococcal and chlamydial urethritis in patients not taking antiretroviral therapy...
  83. doi request reprint Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings
    Andrew N Phillips
    Department of Infection and Population Health, UCL, UK
    AIDS 25:843-50. 2011
    ..There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use...
  84. pmc Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1
    Adele L McCormick
    Centre of Virology, Royal Free and University College London Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom
    Antimicrob Agents Chemother 55:1806-9. 2011
    ..Interestingly, the N348I and M184V double mutation compensated for the reduced NNRTI drug susceptibility observed in the N348I single mutant and marginally improved viral replicative capacity...
  85. pmc Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception
    Susie E Huntington
    UCL Medical School, Royal Free Campus, UK
    AIDS 25:1647-55. 2011
    ....
  86. ncbi request reprint Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection
    Samir Dervisevic
    Department of Virology, Royal Free and University College Medical School, 46 Cleveland Street, London W1T 4JF, UK
    J HIV Ther 8:89-95. 2003
    ....
  87. pmc Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1
    Chris M Parry
    UCL MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, UCL, Windeyer Institute, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Virol 83:9094-101. 2009
    ..Thus, the amino terminus of Gag has a previously unidentified and important function in protease inhibitor susceptibility and replication capacity...
  88. doi request reprint Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women
    Inmaculada Jarrin
    National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
    Am J Epidemiol 168:532-40. 2008
    ..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women...
  89. ncbi request reprint Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase
    Alan Winston
    Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 18:949-51. 2004
  90. ncbi request reprint Update of the Drug Resistance Mutations in HIV-1: 2005
    Victoria A Johnson
    Veterans Affairs Medial Center, Birmingham, AL, USA
    Top HIV Med 13:51-7. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility...
  91. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
    ..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
  92. ncbi request reprint Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice
    Andrew N Phillips
    AIDS 19:487-94. 2005
    ..Little is known about the long term risk of development of HIV-1 drug resistance for patients starting antiretroviral therapy (ART) with three or four drug regimens in routine clinical practice...
  93. ncbi request reprint Long-term persistence of primary genotypic resistance after HIV-1 seroconversion
    David Pao
    Royal Sussex County Hospital, Brighton, United Kingdom
    J Acquir Immune Defic Syndr 37:1570-3. 2004
    ....
  94. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2004
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 12:119-24. 2004
  95. ncbi request reprint Clinically validated genotype analysis: guiding principles and statistical concerns
    Francoise Brun-Vezinet
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:465-78. 2004
    ....
  96. ncbi request reprint Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000
    Paul Scott
    PHLS Antiviral Susceptibility Reference Unit, Birmingham, UK
    J Antimicrob Chemother 53:469-73. 2004
    ..To establish a surveillance programme for HIV drug resistance within the UK covering the years from 1998 to 2000, following the introduction of triple combination antiretroviral therapy...
  97. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  98. ncbi request reprint Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections
    Stephen Taylor
    HPA Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK
    Antivir Ther 8:479-83. 2003
    ..We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1...
  99. ncbi request reprint Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations
    Stephen Taylor
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, Birmingham B9 5SS, UK
    AIDS Res Hum Retroviruses 19:353-61. 2003
    ..We provide "proof of principle" that such mutations can therefore become "fixed" within the circulating virus pool...
  100. ncbi request reprint Resistance tests: what do clinical trials tell us?
    Nicola Price
    J HIV Ther 7:80-6. 2002
    ....
  101. ncbi request reprint HIV viral load: the myth of the undetectable?
    Deenan Pillay
    PHLS Antiviral Susceptibility Reference Unit, Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
    Rev Med Virol 12:391-6. 2002
    ..I also consider other possible uses of HIV-1 quantification in clinical practice, such as identifying the inherent potency of antiviral regimens...